XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Intangible Assets, net (Tables)
3 Months Ended
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Reconciliation of the Activity Affecting Finite Lived Intangible Assets
A reconciliation of the activity affecting intangible assets, net is as follows:
(In thousands)Indefinite-
Lived
Trademarks
Finite-Lived
Trademarks and Customer Relationships
Totals
Gross Carrying Amounts
Balance — March 31, 2022$2,476,559 $436,174 $2,912,733 
Additions
— — — 
Effects of foreign currency exchange rates(6,796)(1,776)(8,572)
Balance — June 30, 20222,469,763 434,398 2,904,161 
    
Accumulated Amortization   
Balance — March 31, 2022— 216,098 216,098 
Additions— 5,635 5,635 
Effects of foreign currency exchange rates— (183)(183)
Balance — June 30, 2022— 221,550 221,550 
Intangible assets, net - June 30, 2022$2,469,763 $212,848 $2,682,611 

On July 1, 2021, we completed the acquisition of certain assets from Akorn (see Note 2) and on December 15, 2021 our Australian subsidiary acquired the rights to the Zaditen brand in certain territories from Novartis Pharma AG. In connection with these acquisitions, we allocated $225.4 million to intangible assets for Akorn and $18.1 million for Zaditen.
Reconciliation of the Activity Affecting Indefinite Lived Intangible Assets
A reconciliation of the activity affecting intangible assets, net is as follows:
(In thousands)Indefinite-
Lived
Trademarks
Finite-Lived
Trademarks and Customer Relationships
Totals
Gross Carrying Amounts
Balance — March 31, 2022$2,476,559 $436,174 $2,912,733 
Additions
— — — 
Effects of foreign currency exchange rates(6,796)(1,776)(8,572)
Balance — June 30, 20222,469,763 434,398 2,904,161 
    
Accumulated Amortization   
Balance — March 31, 2022— 216,098 216,098 
Additions— 5,635 5,635 
Effects of foreign currency exchange rates— (183)(183)
Balance — June 30, 2022— 221,550 221,550 
Intangible assets, net - June 30, 2022$2,469,763 $212,848 $2,682,611 

On July 1, 2021, we completed the acquisition of certain assets from Akorn (see Note 2) and on December 15, 2021 our Australian subsidiary acquired the rights to the Zaditen brand in certain territories from Novartis Pharma AG. In connection with these acquisitions, we allocated $225.4 million to intangible assets for Akorn and $18.1 million for Zaditen.
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
Finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 30 years, and the estimated amortization expense for each of the five succeeding years and the periods thereafter is as follows (in thousands):

(In thousands)
Year Ending March 31,Amount
2023 (remaining nine months ended March 31, 2023)$16,865 
202422,445 
202520,392 
202618,145 
202716,504 
Thereafter118,497 
$212,848